Planegg, Germany
Ethris, founded in 2009 and headquartered in Germany, is a pioneering player in the Biopharma, Biotechnology, and Pharmaceutical industries, notably also making strides in Clean Energy. The company is distinguished by its innovative approach to using its proprietary messenger RNA technology platform to develop therapeutic proteins.
Their slogan, "Ethris is paving a new path from genes to therapeutic proteins using its proprietary messenger RNA technology platform," encapsulates their mission to revolutionize disease treatment through in-house developed transcript therapies. These therapies aim to restore missing functions in patients' cells and tissues, either independently or in collaboration with partners.
Ethris recently drew attention with a $5.00M venture round investment on 18 June 2024, notably from the Bill & Melinda Gates Foundation. This backing underscores investor confidence and highlights the potential impact of their biopharmaceutical advancements on global health.
